Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
01 juin 2022 09h00 HE
|
Recardio Inc.
SAN FRANCISCO, June 01, 2022 (GLOBE NEWSWIRE) -- Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data suggesting potential positive...
Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
23 mai 2022 14h00 HE
|
Recardio Inc.
SAN FRANCISCO, May 23, 2022 (GLOBE NEWSWIRE) -- Entitled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptinin Combination with Filgrastim in Early...
Development: Global Medical Device Manufacturing Outsourcing Market Expected to Surpass $104.3 Million, Rising at 10.3% CAGR from 2019 to 2026 [215-Pages] | Reveals by Research Dive
11 mai 2022 09h06 HE
|
Research Dive
New York, USA, May 11, 2022 (GLOBE NEWSWIRE) -- A new report on the global medical device manufacturing outsourcing market has been added by Research Dive to its repository. According to the report,...
North America Fitness Equipment Market revenue to hit $6bn by 2026, says Graphical Research
04 mai 2022 07h00 HE
|
Graphical Research
Pune, India, May 04, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America fitness equipment market is forecast to register its name in the...
Healios AG Announces Addition of Anna Walz to Board of Directors
12 avr. 2022 14h00 HE
|
Healios AG
BASEL, Switzerland, April 12, 2022 (GLOBE NEWSWIRE) -- Healios AG, a MedTech company focused on developing and validating digital biomarkers since 2014, announced that Anna Walz has been appointed...
Inventiva annonce la présentation d’un abstract scientifique lors de la prochaine International Conference on Fatty Liver
07 avr. 2022 16h00 HE
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 7 avril 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites...
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
07 avr. 2022 16h00 HE
|
INVENTIVA
Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors
06 avr. 2022 09h00 HE
|
Flow Therapy
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors. Dr. Henry is the Lindner Family...
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
08 mars 2022 02h00 HE
|
INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
08 mars 2022 02h00 HE
|
INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...